Patents by Inventor Jianqing Xu
Jianqing Xu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11414487Abstract: The present invention provides PD-1 monoclonal antibodies, particularly human monoclonal antibodies of PD-1, which specifically bind to PD-1 with high affinity and comprise a heavy chain and a light chain. The present invention further provides nucleic acid sequence encoding the antibodies of the invention, cloning or expression vectors, host cells and methods for expressing or isolating the antibodies. Immunoconjugates, therapeutic compositions comprising the antibodies of the invention are also provided. The invention also provides methods for treating various cancers with anti-PD-1 antibodies.Type: GrantFiled: September 21, 2016Date of Patent: August 16, 2022Assignees: CStone Pharmaceuticals, CStone Pharmaceuticals (Suzhou) Co., Ltd., CStone Pharmaceuticals (Shanghai) Co., Ltd.Inventors: Yong Zheng, Jing Li, Gennady Gololobov, Xinhua Zhang, Baotian Yang, Zhewei Tang, Dong Li, Jianqing Xu, Zhuozhi Wang
-
Patent number: 11365254Abstract: A bispecific anti-CD3×CD19 polypeptide complex that contains a first antigen-binding moiety of the polypeptide complex and a second antigen-binding moiety, methods of producing the bispecific anti-CD3×CD19 polypeptide complex, methods of treating disease or disorder using the bispecific anti-CD3×CD19 polypeptide complex, polynucleotides encoding the bispecific anti-CD3×CD19 polypeptide complex, vectors and host cells containing said polynucleotides, and compositions and pharmaceutical compositions comprising the bispecific anti-CD3×CD19 polypeptide complex are provided.Type: GrantFiled: September 20, 2018Date of Patent: June 21, 2022Assignee: WUXI BIOLOGICS IRELAND LIMITEDInventors: Jieying Liu, Jianqing Xu, Zhuozhi Wang, Qin Mei, Jing Li
-
Publication number: 20220177839Abstract: A composition for inducing and/or amplifying TSCM in vitro, a culture medium including the composition, and a method for inducing and/or amplifying TSCM in vitro are provided, wherein the composition comprises inducing agents including IL-7 and IL-21. The chimeric antigen receptor T-memory stem cells induced differentiated and amplified by adding the composition can be used directly for reinfusion therapy of patients.Type: ApplicationFiled: March 5, 2019Publication date: June 9, 2022Inventors: Jianqing Xu, Xiaoyan Zhang, Qibin Liao
-
Patent number: 11352411Abstract: Disclosed are a fusion peptide of CD4 helper T cell epitopes, a nucleic acid encoding the same and an immunogenic composition comprising the same. The epitope fusion peptide comprises a cytomegalovirus epitope and an influenza virus epitope. The epitope fusion peptide can substantially improve the level of cellular immune response to a target immunogen, particularly a weak immunogen, and is an effective means for overcoming the immune tolerance of immune system to an antigen, particularly to a tumor antigen or an infection-related antigen, and is suitable for efficiently enhancing the efficacy of vaccine.Type: GrantFiled: September 28, 2018Date of Patent: June 7, 2022Assignee: Vacdiagn Biotechnology Co., LtdInventors: Jianqing Xu, Yang Huang, Xiaoyan Zhang
-
Publication number: 20220162312Abstract: The present disclosure provides a bispecific anti-CD3×CD20 polypeptide complex that contains a first antigen-binding moiety of the polypeptide complex and a second antigen-binding moiety, methods of producing the bispecific anti-CD3×CD20 polypeptide complex, methods of treating disease or disorder using the bispecific anti-CD3×CD20 polypeptide complex, polynucleotides encoding the bispecific anti-CD3×CD20 polypeptide complex, vectors and host cells containing said polynucleotides, and compositions and pharmaceutical compositions comprising the bispecific anti-CD3×CD20 polypeptide complex.Type: ApplicationFiled: January 22, 2020Publication date: May 26, 2022Inventors: Yunying CHEN, Qin MEI, Jianqing XU, Zhuozhi WANG, Jing LI
-
Publication number: 20220118077Abstract: The present disclosure relates to a novel influenza immunogen with broad-spectrum anti-influenza virus effect and the immunization method thereof. The present disclosure provides a novel anti-influenza immunogen whose sequence comprises the amino acid sequence shown in SEQ ID No: 1 and SEQ ID No: 2, or an immunogenic fragment thereof, or a combination thereof. In addition, the present disclosure also provides use of the recombinant vector vaccine using said immunogen in the anti-influenza vaccine, and the immunization method of the recombinant vector vaccine using said immunogen. Through the sequential administration of multiple vector vaccines expressing the novel influenza immunogen, and the combined use of systemic administration and local administration, a high-level T cell immune response is induced in the local respiratory tract, which can produce broad-spectrum protection against multiple influenza virus infections.Type: ApplicationFiled: September 11, 2018Publication date: April 21, 2022Applicant: Shanghai Public Health Clinical CenterInventors: Jianqing XU, Xiaoyan ZHANG, Xinci XIE
-
Publication number: 20220002750Abstract: The present invention provides a recombinant viral vector, an immunogenic composition containing the same, and the use thereof. The recombinant viral vector comprises a polynucleotide encoding a fusion peptide of CD4 helper T cell epitopes, the epitope fusion peptide comprising a cytomegalovirus epitope and/or an influenza virus epitope. The epitope fusion peptide and the recombinant viral vector provided by the present invention can improve the level of cellular immune response to a target immunogen, particularly to a weak immunogen, and overcome the immune tolerance of immune system to an antigen, particularly to a tumor antigen or an infection-related antigen. The products of the present invention are suitable for enhancing the efficacy of vaccines.Type: ApplicationFiled: June 12, 2019Publication date: January 6, 2022Applicant: VACDIAGN BIOTECHNOLOGY CO., LTDInventors: Jianqing Xu, Yang Huang, Xiaoyan Zhang, Lu Wang, Mingquan Gao, Jiahao Sun
-
Publication number: 20210388065Abstract: The present invention provides recombinant monoclonal antibodies that bind to the Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2 or COVID-19) spike protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to SARS-CoV-2 spike protein. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing SARS-CoV-2 activity, thus providing a means of treating or preventing COVID-19 infection in humans. In some embodiments, the invention provides for a combination of one or more antibodies that bind to the SARS-CoV-2 spike protein for use in treating COVID-19 infection. In certain embodiments, the one or more antibodies bind to distinct non-competing epitopes comprised in the receptor binding domain of the SARS-CoV-2 spike protein.Type: ApplicationFiled: April 15, 2020Publication date: December 16, 2021Applicants: ACTIVE MOTIF SHANGHAI LIMITED, SHANGHAI PUBLIC HEALTH CLINICAL CENTER, FUDAN UNIVERSITY, SHANGHAI PUBLIC HEALTH CLINICAL CENTERInventors: Yanan LU, Fei LAN, Jianqing XU, Xi ZHAO, Longfei DING, Yongheng WANG, Jinkai WAN, Shenghui XING, Joseph FERNANDEZ
-
Publication number: 20210340252Abstract: Provided in the present disclosure are anti-TIM-3 antibodies, the methods of hybridoma generation, the nucleic acid molecules encoding the anti-TIM-3 antibodies, expression vectors and host cells used for the expression of anti-TIM-3 antibodies. The disclosure further provides the methods for validating the function of antibodies in vitro and the efficacy of antibodies in vivo. The antibodies of the disclosure provide a very potent agent for the treatment of cancers via modulating immune functions.Type: ApplicationFiled: December 11, 2019Publication date: November 4, 2021Applicant: WUXI BIOLOGICS IRELAND LIMITEDInventors: Siwei NIE, Yong ZHENG, Jun PAN, Jianqing XU, Jing LI
-
Patent number: 11078281Abstract: The present invention provides CTLA-4 monoclonal antibodies, particularly humanized monoclonal antibodies specifically binding to CTLA-4 with high affinity. The present invention also provides functional monoclonal antibodies cross-reactive to CTLA-4 of human, cynomolgus monkey and mouse. The present invention further provides amino acid sequences of the antibodies of the invention, cloning or expression vectors, host cells and methods for expressing or isolating the antibodies. The epitopes of the antibodies are identified. Therapeutic compositions comprising the antibodies of the invention are also provided. The invention also provides methods for treating cancers and other diseases with anti-CTLA-4 antibodies.Type: GrantFiled: August 6, 2020Date of Patent: August 3, 2021Assignee: WUXI Biologies (Shanghai) Co., Ltd.Inventors: Zhuozhi Wang, Jing Li, Gennady Gololobov, Jianqing Xu
-
Publication number: 20210040214Abstract: The present invention provides CTLA-4 monoclonal antibodies, particularly humanized monoclonal antibodies specifically binding to CTLA-4 with high affinity. The present invention also provides functional monoclonal antibodies cross-reactive to CTLA-4 of human, cynomolgus monkey and mouse. The present invention further provides amino acid sequences of the antibodies of the invention, cloning or expression vectors, host cells and methods for expressing or isolating the antibodies. The epitopes of the antibodies are identified. Therapeutic compositions comprising the antibodies of the invention are also provided. The invention also provides methods for treating cancers and other diseases with anti-CTLA-4 antibodies.Type: ApplicationFiled: August 6, 2020Publication date: February 11, 2021Inventors: Zhuozhi WANG, Jing LI, Gennady GOLOLOBOV, Jianqing XU
-
Publication number: 20200283524Abstract: A polypeptide complex comprises antibody variable regions of the heavy chain and light chain respectively fused to TCR constant regions. A bispecific antigen binding polypeptide complex contains a first antigen-binding moiety of the polypeptide complex and a second antigen-binding moiety. A method comprises producing the polypeptide complex or the bispecific antigen binding polypeptide complex. A method of treating disease or disorder comprises using the polypeptide complex or the bispecific antigen binding polypeptide complex. A polynucleotide encodes the polypeptide complex and/or the bispecific antigen binding polypeptide complex. A vector or a host cell contains the polynucleotide. A composition and a pharmaceutical composition comprise the polypeptide complex and/or the bispecific antigen binding polypeptide complex.Type: ApplicationFiled: September 20, 2018Publication date: September 10, 2020Inventors: Jianqing XU, Zhuozhi WANG, Jing LI
-
Publication number: 20200283523Abstract: A bispecific anti-CD3×CD19 polypeptide complex that contains a first antigen-binding moiety of the polypeptide complex and a second antigen-binding moiety, methods of producing the bispecific anti-CD3×CD19 polypeptide complex, methods of treating disease or disorder using the bispecific anti-CD3×CD19 polypeptide complex, polynucleotides encoding the bispecific anti-CD3×CD19 polypeptide complex, vectors and host cells containing said polynucleotides, and compositions and pharmaceutical compositions comprising the bispecific anti-CD3×CD19 polypeptide complex are provided.Type: ApplicationFiled: September 20, 2018Publication date: September 10, 2020Inventors: Jieying LIU, Jianqing XU, Zhuozhi WANG, Qin MEI, Jing LI
-
Publication number: 20200277377Abstract: The present invention provides CTLA-4 monoclonal antibodies, particularly humanized monoclonal antibodies specifically binding to CTLA-4 with high affinity. The present invention also provides functional monoclonal antibodies cross-reactive to CTLA-4 of human, cynomolgus monkey and mouse. The present invention further provides amino acid sequences of the antibodies of the invention, cloning or expression vectors, host cells and methods for expressing or isolating the antibodies. The epitopes of the antibodies are identified. Therapeutic compositions comprising the antibodies of the invention are also provided. The invention also provides methods for treating cancers and other diseases with anti-CTLA-4 antibodies.Type: ApplicationFiled: May 19, 2017Publication date: September 3, 2020Applicant: WUXI Biologics (Shanghai) Co., Ltd.Inventors: Zhuozhi WANG, Jing LI, Gennady GOLOLOBOV, Jianqing XU
-
Publication number: 20200216516Abstract: Disclosed are a fusion peptide of CD4 helper T cell epitopes, a nucleic acid encoding the same and an immunogenic composition comprising the same. The epitope fusion peptide comprises a cytomegalovirus epitope and an influenza virus epitope. The epitope fusion peptide can substantially improve the level of cellular immune response to a target immunogen, particularly a weak immunogen, and is an effective means for overcoming the immune tolerance of immune system to an antigen, particularly to a tumor antigen or an infection-related antigen, and is suitable for efficiently enhancing the efficacy of vaccine.Type: ApplicationFiled: September 28, 2018Publication date: July 9, 2020Applicant: VACDIAGN BIOTECHNOLOGY CO., LTDInventors: Jianqing Xu, Yang Huang, Xiaoyan Zhang
-
Publication number: 20200063103Abstract: Disclosed is a method for rapidly amplifying CD8+ T cells and functional cell subpopulations thereof in vitro. A TLR1/2 agonist, a TLR2/6 agonist and a TLR5 agonist or a combination of above agonists is added to a conventional culture system for in-vitro amplification of CD8+ T cells. Recombinant cytokines IL-2, IL-7 and IL-15 as well as magnetic beads coated with an anti-human CD3 antibody and an anti-human CD28 antibody can be further added to the culture system for continuous co-stimulation.Type: ApplicationFiled: December 15, 2017Publication date: February 27, 2020Inventors: Jianqing Xu, Xiaoyan Zhang, Chenli Qiu
-
Patent number: 10543731Abstract: A system for decreasing the response time of a vehicle heating ventilation and air conditioning (“HVAC”) system is described. A fan circulates air through a HVAC casing. Circulating air through the HVAC casing creates a high-pressure zone within the HVAC casing. A thermal expansion valve is located outside of the HVAC casing. An outlet port is located on the HVAC casing to allow air to be ported from the high-pressure zone toward the thermal expansion valve. Air ported from the high-pressure zone may be directed toward the thermal expansion valve by a nozzle. The air increases the temperature of the thermal expansion valve and allows additional refrigerant to flow through the thermal expansion valve.Type: GrantFiled: February 15, 2013Date of Patent: January 28, 2020Assignee: FORD GLOBAL TECHNOLOGIES, LLCInventors: Mark Gruenberg, Jianqing Xu, Shahid Bashir
-
Publication number: 20200002420Abstract: The present invention provides PD-1 monoclonal antibodies, particularly human monoclonal antibodies of PD-1, which specifically bind to PD-1 with high affinity and comprise a heavy chain and a light chain. The present invention further provides nucleic acid sequence encoding the antibodies of the invention, cloning or expression vectors, host cells and methods for expressing or isolating the antibodies. Immunoconjugates, therapeutic compositions comprising the antibodies of the invention are also provided. The invention also provides methods for treating various cancers with anti-PD-1 antibodies.Type: ApplicationFiled: September 21, 2016Publication date: January 2, 2020Inventors: Yong ZHENG, Jing LI, Gennady GOLOLOBOV, Xinhua ZHANG, Baotian YANG, Zhewei TANG, Dong LI, Jianqing XU, Zhuozhi WANG
-
Publication number: 20190367875Abstract: The present invention relates to a method for inducing amplification of human type I NKT cells in vitro using a “specific stimulant+staged cytokine” mode, which consists of two culture stages, wherein the first culture stage focuses on specific amplification of the number of the type I NKT cells, in which a specific stimulant ?-GalCer is used to advantageously amplify the type I NKT cells and ?-GalCer-loaded CD1d-expressing cells are used to stimulate continuous proliferation of the type I NKT cells while adding cytokines IL-2 and IL-7 to assist growth of the type I NKT cells; and the second culture stage is to synchronously perform amplification of the number of the type I NKT cells and guide directed function differentiation, in which CD1d-expressing cells incubated with ?-GalCer continue to stimulate proliferation of the type I NKT cells while adding IL-2, IL-7 and IL-15 to assist amplification of the type I NKT cells and guide differentiation, and IL-12 is added to the culture system 1-2 days before the eType: ApplicationFiled: November 1, 2017Publication date: December 5, 2019Inventors: Jianqing Xu, Xiaoyan Zhang, Jing Wang, Lingyan Zhu
-
Patent number: D914301Type: GrantFiled: February 18, 2019Date of Patent: March 23, 2021Inventor: Jianqing Xu